Abiraterone
The serum concentration of Formoterol can be increased when it is combined with Abiraterone.
Acebutolol
Acebutolol may decrease the bronchodilatory activities of Formoterol.
Acepromazine
Acepromazine may decrease the vasoconstricting activities of Formoterol.
Advertisement
Acetyl Sulfisoxazole
The metabolism of Formoterol can be decreased when combined with Acetyl sulfisoxazole.
Alfuzosin
Alfuzosin may decrease the vasoconstricting activities of Formoterol.
Alprenolol
Alprenolol may decrease the bronchodilatory activities of Formoterol.
Advertisement
AMBROXOL ACEFYLLINATE
The risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Formoterol.
Ambroxol-Theophylline-7-Acetate
The risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Formoterol.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Formoterol.
Advertisement
Aminophylline
The risk or severity of adverse effects can be increased when Aminophylline is combined with Formoterol.
Amiodarone
The metabolism of Formoterol can be decreased when combined with Amiodarone.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Formoterol.
Amoxapine
The therapeutic efficacy of Formoterol can be decreased when used in combination with Amoxapine.
Amphetamine
The risk or severity of adverse effects can be increased when Amphetamine is combined with Formoterol.
Anagrelide
Formoterol may increase the QTc-prolonging activities of Anagrelide.
Apalutamide
The serum concentration of Formoterol can be decreased when it is combined with Apalutamide.
Aprepitant
The metabolism of Formoterol can be increased when combined with Aprepitant.
Aripiprazole
Aripiprazole may decrease the vasoconstricting activities of Formoterol.
Armodafinil
The metabolism of Formoterol can be decreased when combined with Armodafinil.
Arsenic Trioxide
Formoterol may increase the QTc-prolonging activities of Arsenic trioxide.
Artemether
Formoterol may increase the QTc-prolonging activities of Artemether.
Asenapine
Formoterol may increase the QTc-prolonging activities of Asenapine.
Atenolol
Atenolol may decrease the bronchodilatory activities of Formoterol.
Atomoxetine
Atomoxetine may increase the tachycardic activities of Formoterol.
Atosiban
The risk or severity of adverse effects can be increased when Formoterol is combined with Atosiban.
Azithromycin
Formoterol may increase the QTc-prolonging activities of Azithromycin.
Azosemide
Formoterol may increase the hypokalemic activities of Azosemide.
Bedaquiline
Formoterol may increase the QTc-prolonging activities of Bedaquiline.
Bendroflumethiazide
Formoterol may increase the hypokalemic activities of Bendroflumethiazide.
Benzthiazide
Formoterol may increase the hypokalemic activities of Benzthiazide.
Benzylpenicilloyl polylysine
Formoterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BETAHISTINE
The therapeutic efficacy of Formoterol can be decreased when used in combination with Betahistine.
Betaxolol
The metabolism of Formoterol can be decreased when combined with Betaxolol.
Bisoprolol
Bisoprolol may decrease the bronchodilatory activities of Formoterol.
Bopindolol
Bopindolol may decrease the bronchodilatory activities of Formoterol.
Bortezomib
The metabolism of Formoterol can be decreased when combined with Bortezomib.
Brexpiprazole
Brexpiprazole may decrease the vasoconstricting activities of Formoterol.
Bromocriptine
Bromocriptine may increase the hypertensive and vasoconstricting activities of Formoterol.
Bumetanide
Formoterol may increase the hypokalemic activities of Bumetanide.
Bunazosin
Bunazosin may decrease the vasoconstricting activities of Formoterol.
Bupranolol
Bupranolol may decrease the bronchodilatory activities of Formoterol.
Bupropion
The metabolism of Formoterol can be decreased when combined with Bupropion.
Butriptyline
The risk or severity of adverse effects can be increased when Butriptyline is combined with Formoterol.
Cabergoline
Cabergoline may increase the hypertensive and vasoconstricting activities of Formoterol.
Caffeine
The risk or severity of adverse effects can be increased when Caffeine is combined with Formoterol.
Capecitabine
The metabolism of Formoterol can be decreased when combined with Capecitabine.
Carbamazepine
The metabolism of Formoterol can be increased when combined with Carbamazepine.
Carteolol
Carteolol may decrease the bronchodilatory activities of Formoterol.
Carvedilol
Carvedilol may decrease the vasoconstricting activities of Formoterol.
Celecoxib
The metabolism of Formoterol can be decreased when combined with Celecoxib.
Celiprolol
Celiprolol may decrease the bronchodilatory activities of Formoterol.
Ceritinib
The serum concentration of Formoterol can be increased when it is combined with Ceritinib.
Chloramphenicol
The metabolism of Formoterol can be decreased when combined with Chloramphenicol.
Chloroquine
The metabolism of Formoterol can be decreased when combined with Chloroquine.
Chlorothiazide
Formoterol may increase the hypokalemic activities of Chlorothiazide.
Chlorpromazine
The metabolism of Formoterol can be decreased when combined with Chlorpromazine.
Chlorthalidone
Formoterol may increase the hypokalemic activities of Chlorthalidone.
Cholecalciferol
The metabolism of Formoterol can be decreased when combined with Cholecalciferol.
Cimetidine
The metabolism of Formoterol can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Formoterol can be decreased when combined with Cinacalcet.
Ciprofloxacin
Formoterol may increase the QTc-prolonging activities of Ciprofloxacin.
Cisapride
Formoterol may increase the QTc-prolonging activities of Cisapride.
Citalopram
Formoterol may increase the QTc-prolonging activities of Citalopram.
Clarithromycin
Formoterol may increase the QTc-prolonging activities of Clarithromycin.
Clemastine
The metabolism of Formoterol can be decreased when combined with Clemastine.
Clobazam
The metabolism of Formoterol can be decreased when combined with Clobazam.
Clomipramine
The metabolism of Formoterol can be decreased when combined with Clomipramine.
Clotrimazole
The metabolism of Formoterol can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Formoterol can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Formoterol can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Formoterol can be decreased when combined with Cocaine.
Crisaborole
The metabolism of Formoterol can be decreased when combined with Crisaborole.
Crizotinib
Formoterol may increase the QTc-prolonging activities of Crizotinib.
Curcumin
The metabolism of Formoterol can be decreased when combined with Curcumin.
Cyclopenthiazide
Formoterol may increase the hypokalemic activities of Cyclopenthiazide.
Cyclosporine
The metabolism of Formoterol can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Formoterol can be decreased when it is combined with Dabrafenib.
Dapiprazole
Dapiprazole may decrease the vasoconstricting activities of Formoterol.
Darifenacin
The metabolism of Formoterol can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Formoterol can be increased when it is combined with Darunavir.
Delavirdine
The metabolism of Formoterol can be decreased when combined with Delavirdine.
Desflurane
Desflurane may increase the arrhythmogenic activities of Formoterol.
Desipramine
The metabolism of Formoterol can be decreased when combined with Desipramine.
Desvenlafaxine
Desvenlafaxine may increase the tachycardic activities of Formoterol.
Dextroamphetamine
Dextroamphetamine may decrease the vasoconstricting activities of Formoterol.
Dihydroergotamine
Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Formoterol.
Diphenhydramine
The metabolism of Formoterol can be decreased when combined with Diphenhydramine.
Disopyramide
Formoterol may increase the QTc-prolonging activities of Disopyramide.
Dofetilide
Formoterol may increase the QTc-prolonging activities of Dofetilide.
Dolasetron
Formoterol may increase the QTc-prolonging activities of Dolasetron.
Domperidone
Formoterol may increase the QTc-prolonging activities of Domperidone.
Dothiepin
The metabolism of Formoterol can be decreased when combined with Dosulepin.
Doxazosin
Doxazosin may decrease the vasoconstricting activities of Formoterol.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Formoterol.
Dronedarone
Formoterol may increase the QTc-prolonging activities of Dronedarone.
Droperidol
Formoterol may increase the QTc-prolonging activities of Droperidol.
Duloxetine
Duloxetine may increase the tachycardic activities of Formoterol.
Dyphylline
The risk or severity of adverse effects can be increased when Dyphylline is combined with Formoterol.
Efavirenz
The metabolism of Formoterol can be decreased when combined with Efavirenz.
Eliglustat
Formoterol may increase the QTc-prolonging activities of Eliglustat.
Enflurane
Enflurane may increase the arrhythmogenic activities of Formoterol.
Epinephrine
Epinephrine may decrease the vasoconstricting activities of Formoterol.
ergoloid mesylates, USP
Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Formoterol.
Ergonovine
Ergonovine may increase the hypertensive and vasoconstricting activities of Formoterol.
Ergotamine
Ergotamine may increase the hypertensive and vasoconstricting activities of Formoterol.
Erythromycin
Formoterol may increase the QTc-prolonging activities of Erythromycin.
Escitalopram
Formoterol may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine Acetate
The metabolism of Formoterol can be decreased when combined with Eslicarbazepine acetate.
Esmolol
Esmolol may decrease the bronchodilatory activities of Formoterol.
Esomeprazole
The metabolism of Formoterol can be decreased when combined with Esomeprazole.
Ethacrynate
Formoterol may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Formoterol may increase the hypokalemic activities of Etacrynic acid.
Etravirine
The metabolism of Formoterol can be decreased when combined with Etravirine.
Flecainide
Formoterol may increase the QTc-prolonging activities of Flecainide.
Floxuridine
The metabolism of Formoterol can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Formoterol can be decreased when combined with Fluconazole.
Fluorouracil
The metabolism of Formoterol can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Formoterol can be decreased when combined with Fluoxetine.
Flupenthixol
Formoterol may increase the QTc-prolonging activities of Flupentixol.
Fluvastatin
The metabolism of Formoterol can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Formoterol can be decreased when combined with Fluvoxamine.
Fosphenytoin
The metabolism of Formoterol can be increased when combined with Fosphenytoin.
Furazolidone
The risk or severity of adverse effects can be increased when Furazolidone is combined with Formoterol.
Furosemide
Formoterol may increase the hypokalemic activities of Furosemide.
Gadobenate
Formoterol may increase the QTc-prolonging activities of Gadobenic acid.
Gemfibrozil
The metabolism of Formoterol can be decreased when combined with Gemfibrozil.
Gemifloxacin
Formoterol may increase the QTc-prolonging activities of Gemifloxacin.
Gemifloxacin Mesylate
Formoterol may increase the QTc-prolonging activities of Gemifloxacin.
Goserelin
Formoterol may increase the QTc-prolonging activities of Goserelin.
Granisetron
Formoterol may increase the QTc-prolonging activities of Granisetron.
Haloperidol
The metabolism of Formoterol can be decreased when combined with Haloperidol.
Halothane
Halothane may increase the arrhythmogenic activities of Formoterol.
Hydrochlorothiazide
Formoterol may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Formoterol may increase the hypokalemic activities of Hydroflumethiazide.
Ibutilide
Formoterol may increase the QTc-prolonging activities of Ibutilide.
Iloperidone
Formoterol may increase the QTc-prolonging activities of Iloperidone.
Imipramine
The metabolism of Formoterol can be decreased when combined with Imipramine.
Indapamide
Formoterol may increase the hypokalemic activities of Indapamide.
Indinavir
The metabolism of Formoterol can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Formoterol can be decreased when combined with Indinavir.
Indoramin
Indoramin may decrease the vasoconstricting activities of Formoterol.
Iproniazid
The risk or severity of adverse effects can be increased when Iproniazid is combined with Formoterol.
Irbesartan
The metabolism of Formoterol can be decreased when combined with Irbesartan.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Formoterol.
Isoflurane
Isoflurane may increase the arrhythmogenic activities of Formoterol.
Isoniazid
The metabolism of Formoterol can be decreased when combined with Isoniazid.
Ketoconazole
The metabolism of Formoterol can be decreased when combined with Ketoconazole.
Labetalol
Labetalol may decrease the vasoconstricting activities of Formoterol.
Leflunomide
The metabolism of Formoterol can be decreased when combined with Leflunomide.
Lenvatinib
Formoterol may increase the QTc-prolonging activities of Lenvatinib.
Lenvatinib Mesylate
Formoterol may increase the QTc-prolonging activities of Lenvatinib.
Leuprolide
Formoterol may increase the QTc-prolonging activities of Leuprolide.
Levofloxacin
Formoterol may increase the QTc-prolonging activities of Levofloxacin.
Levofloxacin Anhydrous
Formoterol may increase the QTc-prolonging activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the tachycardic activities of Formoterol.
Lisdexamfetamine
Lisdexamfetamine may decrease the vasoconstricting activities of Formoterol.
Lisdexamfetamine Dimesylate
Lisdexamfetamine may decrease the vasoconstricting activities of Formoterol.
Lopinavir
The metabolism of Formoterol can be decreased when combined with Lopinavir.
Lorcaserin
The metabolism of Formoterol can be decreased when combined with Lorcaserin.
Losartan
The metabolism of Formoterol can be decreased when combined with Losartan.
Lovastatin
The metabolism of Formoterol can be decreased when combined with Lovastatin.
Loxapine
The therapeutic efficacy of Formoterol can be decreased when used in combination with Loxapine.
Luliconazole
The serum concentration of Formoterol can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Formoterol can be decreased when it is combined with Lumacaftor.
Lumefantrine
Formoterol may increase the QTc-prolonging activities of Lumefantrine.
Manidipine
The metabolism of Formoterol can be decreased when combined with Manidipine.
MELITRACEN
The risk or severity of adverse effects can be increased when Melitracen is combined with Formoterol.
Mepindolol
Mepindolol may decrease the bronchodilatory activities of Formoterol.
Methadone
The metabolism of Formoterol can be decreased when combined with Methadone.
Methotrimeprazine
The metabolism of Formoterol can be decreased when combined with Methotrimeprazine.
Methoxyflurane
Methoxyflurane may increase the arrhythmogenic activities of Formoterol.
Methyclothiazide
Formoterol may increase the hypokalemic activities of Methyclothiazide.
Methylene blue
The risk or severity of adverse effects can be increased when Methylene blue is combined with Formoterol.
Methylergonovine
Methylergometrine may increase the hypertensive and vasoconstricting activities of Formoterol.
Metolazone
Formoterol may increase the hypokalemic activities of Metolazone.
Metoprolol
The metabolism of Formoterol can be decreased when combined with Metoprolol.
Midostaurin
The metabolism of Formoterol can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Formoterol can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the tachycardic activities of Formoterol.
Minaprine
The risk or severity of adverse effects can be increased when Minaprine is combined with Formoterol.
Mirabegron
The metabolism of Formoterol can be decreased when combined with Mirabegron.
Moclobemide
The metabolism of Formoterol can be decreased when combined with Moclobemide.
Modafinil
The metabolism of Formoterol can be decreased when combined with Modafinil.
Moxifloxacin
Formoterol may increase the QTc-prolonging activities of Moxifloxacin.
Nabilone
The metabolism of Formoterol can be decreased when combined with Nabilone.
Nadolol
Nadolol may decrease the bronchodilatory activities of Formoterol.
Nebivolol
Nebivolol may decrease the bronchodilatory activities of Formoterol.
Nefazodone
Nefazodone may decrease the vasoconstricting activities of Formoterol.
Nelfinavir
The metabolism of Formoterol can be decreased when combined with Nelfinavir.
Nevirapine
The metabolism of Formoterol can be decreased when combined with Nevirapine.
Nialamide
The risk or severity of adverse effects can be increased when Nialamide is combined with Formoterol.
Nicardipine
The metabolism of Formoterol can be decreased when combined with Nicardipine.
Nicergoline
Nicergoline may decrease the vasoconstricting activities of Formoterol.
Nicotine
The metabolism of Formoterol can be decreased when combined with Nicotine.
Nicotine Polacrilex
The metabolism of Formoterol can be decreased when combined with Nicotine.
Nilotinib
Formoterol may increase the QTc-prolonging activities of Nilotinib.
Nitrous Oxide
Nitrous oxide may increase the arrhythmogenic activities of Formoterol.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Formoterol.
Ofloxacin
Formoterol may increase the QTc-prolonging activities of Ofloxacin.
Olanzapine
Olanzapine may decrease the vasoconstricting activities of Formoterol.
Omeprazole
The metabolism of Formoterol can be decreased when combined with Omeprazole.
Ondansetron
Formoterol may increase the QTc-prolonging activities of Ondansetron.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Formoterol.
Oxprenolol
Oxprenolol may decrease the bronchodilatory activities of Formoterol.
Paliperidone
Formoterol may increase the QTc-prolonging activities of Paliperidone.
Panobinostat
The serum concentration of Formoterol can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Formoterol can be decreased when combined with Pantoprazole.
Pargyline
The risk or severity of adverse effects can be increased when Pargyline is combined with Formoterol.
Paroxetine
The metabolism of Formoterol can be decreased when combined with Paroxetine.
Pazopanib
Formoterol may increase the QTc-prolonging activities of Pazopanib.
Peginterferon Alfa-2b
The serum concentration of Formoterol can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Penbutolol may decrease the bronchodilatory activities of Formoterol.
Pentamidine
Formoterol may increase the QTc-prolonging activities of Pentamidine.
Pentobarbital
The metabolism of Formoterol can be increased when combined with Pentobarbital.
Perflutren
Formoterol may increase the QTc-prolonging activities of Perflutren.
Periciazine
Propericiazine may decrease the vasoconstricting activities of Formoterol.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Formoterol.
Phenobarbital
The metabolism of Formoterol can be increased when combined with Phenobarbital.
Phenoxybenzamine
Phenoxybenzamine may decrease the vasoconstricting activities of Formoterol.
Phentolamine
Phentolamine may decrease the vasoconstricting activities of Formoterol.
Phentolamine Mesylate
Phentolamine may decrease the vasoconstricting activities of Formoterol.
Phenytoin
The metabolism of Formoterol can be increased when combined with Phenytoin.
Pimozide
Formoterol may increase the QTc-prolonging activities of Pimozide.
Pindolol
Pindolol may decrease the bronchodilatory activities of Formoterol.
Piretanide
Formoterol may increase the hypokalemic activities of Piretanide.
Pizotyline
Pizotifen may decrease the vasoconstricting activities of Formoterol.
Polythiazide
Formoterol may increase the hypokalemic activities of Polythiazide.
Prazosin
Prazosin may decrease the vasoconstricting activities of Formoterol.
Primaquine
Formoterol may increase the QTc-prolonging activities of Primaquine.
Primidone
The metabolism of Formoterol can be increased when combined with Primidone.
Procainamide
Formoterol may increase the QTc-prolonging activities of Procainamide.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Formoterol.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Formoterol.
Promazine
The metabolism of Formoterol can be decreased when combined with Promazine.
Propafenone
Formoterol may increase the QTc-prolonging activities of Propafenone.
Propiomazine
Propiomazine may decrease the vasoconstricting activities of Formoterol.
Propiverine
Propiverine may decrease the vasoconstricting activities of Formoterol.
Propranolol
Propranolol may decrease the bronchodilatory activities of Formoterol.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Formoterol.
Pyrimethamine
The metabolism of Formoterol can be decreased when combined with Pyrimethamine.
Quetiapine
Formoterol may increase the QTc-prolonging activities of Quetiapine.
Quetiapine fumarate
Formoterol may increase the QTc-prolonging activities of Quetiapine.
Quinethazone
Formoterol may increase the hypokalemic activities of Quinethazone.
Quinidine
The metabolism of Formoterol can be decreased when combined with Quinidine.
Quinine
Formoterol may increase the QTc-prolonging activities of Quinine.
Racepinephrine
Racepinephrine may decrease the vasoconstricting activities of Formoterol.
Ranolazine
The metabolism of Formoterol can be decreased when combined with Ranolazine.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Formoterol.
Rifampin
The metabolism of Formoterol can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Formoterol can be increased when combined with Rifapentine.
Risperidone
Risperidone may decrease the vasoconstricting activities of Formoterol.
Ritonavir
The metabolism of Formoterol can be decreased when combined with Ritonavir.
Rolapitant
The metabolism of Formoterol can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Formoterol can be decreased when combined with Ropinirole.
Rucaparib
The metabolism of Formoterol can be decreased when combined with Rucaparib.
Saquinavir
Formoterol may increase the QTc-prolonging activities of Saquinavir.
Saquinavir Mesylate
Formoterol may increase the QTc-prolonging activities of Saquinavir.
Secobarbital
The metabolism of Formoterol can be increased when combined with Secobarbital.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Formoterol.
Sertraline
The metabolism of Formoterol can be decreased when combined with Sertraline.
Sevoflurane
Sevoflurane may increase the arrhythmogenic activities of Formoterol.
Sildenafil
The metabolism of Formoterol can be decreased when combined with Sildenafil.
Silodosin
Silodosin may decrease the vasoconstricting activities of Formoterol.
Sorafenib
The metabolism of Formoterol can be decreased when combined with Sorafenib.
Sotalol
Sotalol may decrease the bronchodilatory activities of Formoterol.
Spironolactone
Spironolactone may decrease the vasoconstricting activities of Formoterol.
Sulfadiazine
The metabolism of Formoterol can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Formoterol can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Formoterol can be decreased when combined with Sulfisoxazole.
Tamsulosin
Tamsulosin may decrease the vasoconstricting activities of Formoterol.
Telavancin
Formoterol may increase the QTc-prolonging activities of Telavancin.
Telithromycin
Formoterol may increase the QTc-prolonging activities of Telithromycin.
Terazosin
Terazosin may decrease the vasoconstricting activities of Formoterol.
Terbinafine
The metabolism of Formoterol can be decreased when combined with Terbinafine.
Tertatolol
Tertatolol may decrease the bronchodilatory activities of Formoterol.
Tetrabenazine
Formoterol may increase the QTc-prolonging activities of Tetrabenazine.
Theophylline
The risk or severity of adverse effects can be increased when Theophylline is combined with Formoterol.
Theophylline anhydrous
The risk or severity of adverse effects can be increased when Theophylline is combined with Formoterol.
Thioproperazine
Thioproperazine may decrease the vasoconstricting activities of Formoterol.
Thioridazine
The metabolism of Formoterol can be decreased when combined with Thioridazine.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Formoterol.
Ticagrelor
The metabolism of Formoterol can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Formoterol can be decreased when combined with Ticlopidine.
Timolol
Timolol may decrease the bronchodilatory activities of Formoterol.
Timolol Anhydrous
Timolol may decrease the bronchodilatory activities of Formoterol.
Tipranavir
The metabolism of Formoterol can be decreased when combined with Tipranavir.
Tolazoline
Tolazoline may decrease the vasoconstricting activities of Formoterol.
Tolbutamide
The metabolism of Formoterol can be decreased when combined with Tolbutamide.
Toloxatone
The risk or severity of adverse effects can be increased when Toloxatone is combined with Formoterol.
Topiramate
The metabolism of Formoterol can be decreased when combined with Topiramate.
Toremifene
Formoterol may increase the QTc-prolonging activities of Toremifene.
Torsemide
Formoterol may increase the hypokalemic activities of Torasemide.
Tranylcypromine
The metabolism of Formoterol can be decreased when combined with Tranylcypromine.
Trazodone
Trazodone may decrease the vasoconstricting activities of Formoterol.
Trichlormethiazide
Formoterol may increase the hypokalemic activities of Trichlormethiazide.
Trifluoperazine
Trifluoperazine may decrease the vasoconstricting activities of Formoterol.
Trimethoprim
The metabolism of Formoterol can be decreased when combined with Trimethoprim.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Formoterol.
Urapidil
Urapidil may decrease the vasoconstricting activities of Formoterol.
Valproate
The metabolism of Formoterol can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Formoterol can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Formoterol can be decreased when combined with Valsartan.
Vandetanib
Formoterol may increase the QTc-prolonging activities of Vandetanib.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Formoterol.
Venlafaxine
Venlafaxine may increase the tachycardic activities of Formoterol.
Verapamil
Verapamil may decrease the vasoconstricting activities of Formoterol.
Voriconazole
The metabolism of Formoterol can be decreased when combined with Voriconazole.
Zafirlukast
The metabolism of Formoterol can be decreased when combined with Zafirlukast.
Ziprasidone
Formoterol may increase the QTc-prolonging activities of Ziprasidone.
Zuclopenthixol
Formoterol may increase the QTc-prolonging activities of Zuclopenthixol.
